MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
4.060
+0.020
+0.50%
After Hours: 4.020 -0.04 -0.99% 18:58 07/02 EDT
OPEN
4.040
PREV CLOSE
4.040
HIGH
4.115
LOW
3.860
VOLUME
645.49K
TURNOVER
--
52 WEEK HIGH
7.82
52 WEEK LOW
2.770
MARKET CAP
228.19M
P/E (TTM)
-3.0027
1D
5D
1M
3M
1Y
5Y
1D
Top Executive Makes Major Move With Protara Therapeutics Stock Sale
TipRanks · 1d ago
Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83
PUBT · 1d ago
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Protara Therapeutics (TARA)
TipRanks · 1d ago
Protara Therapeutics Announces Key Medical Leadership Transition
TipRanks · 3d ago
Protara Therapeutics CMO Nicacio resigns effective June 26, 2026
PUBT · 3d ago
Weekly Report: what happened at TARA last week (0622-0626)?
Weekly Report · 4d ago
Weekly Report: what happened at TARA last week (0615-0619)?
Weekly Report · 06/22 10:11
Protara Therapeutics Stockholders Approve Governance and Share Increases
TipRanks · 06/15 21:06
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.